Biogen raises annual earnings guidance, tops Q3 estimates; shares up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Biogen (BIIB) PT Lowered to $260 at RBC Capital
October 31, 2024 6:31 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $269.00) while maintaining a Outperform rating.
The analyst comments "3Q showed BIIB remains a company in transition, with some bright spots like ex-U.S. Leqembi, improving operating... More
Biogen (BIIB) PT Raised to $315 at Piper Sandler
October 30, 2024 4:54 PM EDTPiper Sandler analyst Christopher Raymond raised the price target on Biogen (NASDAQ: BIIB) to $315.00 (from $307.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BIIB shares after a solid Q324 beat/FY24 guidance raise. While some may quibble... More
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
October 30, 2024 4:37 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "BIIB posted in-line 3Q revenue, inclusive of Leqembi's beat and Skyclarys' miss, and higher EPS per cost-savings. Leqembi's launch remains affected by infrastructure/logistical challenges, where we continue to expect a gradual, albeit progressing, uptake curve and are... More
